SCHEDULE: Eventide Asset Management Discloses 13.4% Stake in Beta Bionics

Eventide Asset Management, LLC, along with individuals Finny Kuruvilla and Robin C. John, have reported beneficial ownership of 5,945,488 shares, representing 13.4% of Beta Bionics, Inc.'s common stock as of March 31, 2026.

Summary

• Eventide Asset Management, LLC, and individuals Finny Kuruvilla, M.D., Ph.D., and Robin C. John have filed a Schedule 13G, indicating their beneficial ownership of Beta Bionics, Inc. common stock.
• The total number of shares beneficially owned by these entities is 5,945,488, which constitutes 13.4% of the class of securities.
• This ownership is held through Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, and Eventide's separately managed accounts.
• Eventide Gilead Fund holds 3,750,973 shares (8.5%), Eventide Healthcare & Life Sciences Fund holds 2,052,176 shares (4.6%), and separately managed accounts hold 142,339 shares (0.3%).
• The filing is an amendment, indicating a change in reporting status or holdings.
• The reporting persons disclaim beneficial ownership beyond their actual investment advisory roles.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; it's a standard disclosure of a significant ownership stake by an investment firm, providing information on who holds the shares rather than company performance or future prospects.

Positives

• Significant ownership stake of 13.4% by Eventide Asset Management and associated individuals in Beta Bionics, Inc.
• The filing indicates active investment management through multiple funds and accounts, suggesting confidence in the company's prospects.
• The reporting persons are registered investment companies and investment advisors, implying a professional and strategic approach to their holdings.

Negatives

• The filing does not contain specific financial performance data for Beta Bionics, Inc., making it difficult to assess the company's current health.
• The nature of the filing (Schedule 13G) suggests a passive investment approach rather than an attempt to influence control, which might limit immediate impact on company strategy.

Risks

• The filing does not explicitly detail risks associated with Beta Bionics, Inc. itself, as it is a disclosure of ownership rather than a company performance report.
• Potential for future changes in ownership by Eventide Asset Management could impact share price and stability.

Future Outlook

The filing does not contain forward-looking statements or guidance from Beta Bionics, Inc. It is a disclosure of beneficial ownership by Eventide Asset Management and associated individuals.

Management Comments

• Each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by Eventide Asset Management signifies a substantial institutional investment in Beta Bionics, Inc., a company likely operating in the biotechnology or medical device sector. Such filings often precede or follow significant corporate developments, and a 13.4% stake indicates a notable position for an investment advisor.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor like Eventide may influence market perception and potentially attract further investment.
• Management of Beta Bionics, Inc.: The substantial stake held by Eventide may lead to increased engagement or scrutiny from the investment firm.
• Creditors: While not directly impacted by this ownership filing, the stability and financial health of Beta Bionics, Inc., as reflected in its own disclosures, would be of interest.

Next Steps

• Monitor future filings from Eventide Asset Management and Beta Bionics, Inc. for any changes in ownership or company strategy.
• Analyze Beta Bionics, Inc.'s own SEC filings for financial performance, strategic updates, and risk factors.

Key Dates

Keywords

Beta Bionics, Schedule 13G, Eventide Asset Management, Finny Kuruvilla, Robin C. John, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing, Ownership Stake